← All organizations
Highest phase reached
Phase 3
First clinical trial
Sep 1, 1995First marketed drug
Jan 1, 1995First NDA
Dec 28, 1995Last known activity
Dec 1, 2006
Timeline
1970s
- Jun 3, 1977
estropipate— NDA Organization
1990s
- Aug 23, 1991
naltrexone— Marketing Organization
- Aug 7, 1992
cefpodoxime— NDA Secondary Org
- Jan 1, 1995
Pharmacia & Upjohn— Founded
- Jan 1, 1995
Kabi Pharmacia— Acquired
- Jan 2, 1995
Upjohn— Acquired - Jan 1, 1999
Sugen— Acquired
Drugs by trial phase (42 distinct, 39 trials)
Phase 4 (0 own, 2 via acquisition)
Phase 3 (10 own, 12 via acquisition)
Phase 2 (8 own, 4 via acquisition)
Phase 1 (1 own, 1 via acquisition)
Other trials (2 own, 2 via acquisition)
Indications
Approved for
- Abdominal Abscess
- Abscess
- Acne Vulgaris
- Acromegaly
- Adrenal Hyperplasia, Congenital
- Amenorrhea
- Arthritis, Rheumatoid
- Asthma
- Atrial Fibrillation
- Bone Diseases, Infectious
- Breast Neoplasms
- Bursitis
- Cluster Headache
- Colitis, Ulcerative
- Colorectal Neoplasms
- Crohn Disease
- Dermatitis, Contact
- Diabetes Mellitus, Type 2
- Dwarfism, Pituitary
- Dysmenorrhea
- Empyema
- Endometrial Hyperplasia
- Endometritis
- Genital Diseases, Female
- Gigantism
- Glaucoma
- Glaucoma, Open-Angle
- Hand Dermatoses
- Hemorrhage
- HIV Infections
- Hypercholesterolemia
- Hyperprolactinemia
- Hypertension
- Infections
- Inflammation
- Intraabdominal Infections
- Leukemia, Myeloid, Acute
- Lung Abscess
- Lupus Erythematosus, Systemic
- Menorrhagia
- Migraine Disorders
- Multiple Sclerosis
- Mycobacterium avium-intracellulare Infection
- Ocular Hypertension
- Osteoarthritis
- Osteomyelitis
- Parametritis
- Parkinson Disease
- Pelvic Infection
- Pemphigus
- Peritonitis
- Pneumococcal Infections
- Pneumonia
- Postpartum Hemorrhage
- Pregnancy
- Prolactinoma
- Prostatic Neoplasms
- Reproductive Tract Infections
- Respiratory Tract Infections
- Restless Legs Syndrome
- Sepsis
- Skin and Connective Tissue Diseases
- Skin Diseases, Bacterial
- Sleep Disorders, Intrinsic
- Soft Tissue Infections
- Staphylococcal Infections
- Staphylococcal Skin Infections
- Streptococcal Infections
- Urinary Bladder, Overactive
- Urinary Tract Infections
- Uterine Hemorrhage
Marketed drugs (85)
Subsidiaries (3 direct, 7 total across the full acquisition tree)
Recent trials (22)
- NCT00177853CollaboratorPhase 1Dec 1, 2006
- NCT00193596CollaboratorPhase 3Sep 1, 2003
- NCT00193375CollaboratorPhase 2Aug 1, 2003
- NCT00193349CollaboratorPhase 2Sep 1, 2002
- NCT00318903CollaboratorPhase 2Jan 1, 2002
- NCT00193050CollaboratorPhase 2Nov 1, 2001
- NCT00193024CollaboratorPhase 2Sep 1, 2001
- NCT00201747CollaboratorPhase 2Sep 1, 2001
- NCT00002211Lead sponsorN/ANov 2, 1999
- NCT00002210Lead sponsorPhase 2Nov 2, 1999
- NCT00002322Lead sponsorPhase 2Nov 2, 1999
- NCT00002124Lead sponsorPhase 3Nov 2, 1999
- NCT00002087Lead sponsorPhase 1Nov 2, 1999
- NCT00002400Lead sponsorN/ANov 2, 1999
- NCT00002401Lead sponsorN/ANov 2, 1999
Details
- Founded
- London, GB Jan 1, 1995
- First NDA
- Dec 28, 1995
- Last known activity
- Dec 1, 2006
Designations held
- Orphan drug
- Fast track
- Priority review
- Accelerated approval